Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

Beyond KRAS: Practical Molecular Targets in Pancreatic Adenocarcinoma.

Grinshpun A, Zarbiv Y, Roszik J, Subbiah V, Hubert A.

Case Rep Oncol. 2019 Jan 4;12(1):7-13. doi: 10.1159/000496018. eCollection 2019 Jan-Apr.

PMID:
30792639
2.

High-Throughput Architecture for Discovering Combination Cancer Therapeutics.

Gianni M, Qin Y, Wenes G, Bandstra B, Conley AP, Subbiah V, Leibowitz-Amit R, Ekmekcioglu S, Grimm EA, Roszik J.

JCO Clin Cancer Inform. 2018 Dec;2:1-12. doi: 10.1200/CCI.17.00054.

3.

The COX2 Effector Microsomal PGE2 Synthase 1 is a Regulator of Immunosuppression in Cutaneous Melanoma.

Kim SH, Roszik J, Cho SN, Ogata D, Milton DR, Peng W, Menter DG, Ekmekcioglu S, Grimm EA.

Clin Cancer Res. 2018 Dec 11. doi: 10.1158/1078-0432.CCR-18-1163. [Epub ahead of print]

PMID:
30538110
4.

The lncRNA RMEL3 protects immortalized cells from serum withdrawal-induced growth arrest and promotes melanoma cell proliferation and tumor growth.

Cardoso C, Serafim RB, Kawakami A, Gonçalves Pereira C, Roszik J, Valente V, Vazquez VL, Fisher DE, Espreafico EM.

Pigment Cell Melanoma Res. 2019 Mar;32(2):303-314. doi: 10.1111/pcmr.12751. Epub 2018 Dec 16.

PMID:
30457212
5.

Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4.

Villar-Prados A, Wu SY, Court KA, Ma S, LaFargue C, Chowdhury MA, Engelhardt MI, Ivan C, Ram PT, Wang Y, Baggerly K, Rodriguez-Aguayo C, Lopez-Berestein G, Ming-Yang S, Maloney DJ, Yoshioka M, Strovel JW, Roszik J, Sood AK.

Mol Cancer Ther. 2019 Feb;18(2):421-436. doi: 10.1158/1535-7163.MCT-18-0365. Epub 2018 Nov 12.

PMID:
30420565
6.

Beyond autoantibodies: Biological roles of human autoreactive B cells in rheumatoid arthritis revealed by RNA-sequencing.

Mahendra A, Yang X, Abnouf S, Adolacion JRT, Park D, Soomro S, Roszik J, Coarfa C, Romain G, Wanzeck K, Louis Bridges S Jr, Aggarwal A, Qiu P, Agarwal SK, Mohan C, Varadarajan N.

Arthritis Rheumatol. 2018 Nov 8. doi: 10.1002/art.40772. [Epub ahead of print]

PMID:
30407753
7.

Commentary: Nuclear dynamics of the Set1C subunit Spp1 prepares meiotic recombination sites for break formation.

Fillér C, Hornyák L, Roszik J.

Front Genet. 2018 Oct 23;9:496. doi: 10.3389/fgene.2018.00496. eCollection 2018. No abstract available.

8.

Reply to Oegema et al.: CFI-400945 and Polo-like kinase 4 inhibition.

Kawakami M, Mustachio LM, Zheng L, Chen Y, Rodriguez-Canales J, Mino B, Kurie JM, Roszik J, Villalobos PA, Thu KL, Silvester J, Cescon DW, Wistuba II, Mak TW, Liu X, Dmitrovsky E.

Proc Natl Acad Sci U S A. 2018 Nov 13;115(46):E10810-E10811. doi: 10.1073/pnas.1813967115. Epub 2018 Oct 30. No abstract available.

PMID:
30377273
9.

Gene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy.

Roszik J, Ring KL, Wani KM, Lazar AJ, Yemelyanova AV, Soliman PT, Frumovitz M, Jazaeri AA.

Front Immunol. 2018 Sep 19;9:2102. doi: 10.3389/fimmu.2018.02102. eCollection 2018.

10.

A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily.

Korkut A, Zaidi S, Kanchi RS, Rao S, Gough NR, Schultz A, Li X, Lorenzi PL, Berger AC, Robertson G, Kwong LN, Datto M, Roszik J, Ling S, Ravikumar V, Manyam G, Rao A, Shelley S, Liu Y, Ju Z, Hansel D, de Velasco G, Pennathur A, Andersen JB, O'Rourke CJ, Ohshiro K, Jogunoori W, Nguyen BN, Li S, Osmanbeyoglu HU, Ajani JA, Mani SA, Houseman A, Wiznerowicz M, Chen J, Gu S, Ma W, Zhang J, Tong P, Cherniack AD, Deng C, Resar L; Cancer Genome Atlas Research Network, Weinstein JN, Mishra L, Akbani R.

Cell Syst. 2018 Oct 24;7(4):422-437.e7. doi: 10.1016/j.cels.2018.08.010. Epub 2018 Sep 26.

11.

Editorial: Targeting Metabolism in Cancer Immunotherapy.

Roszik J, Tanese K, Ekmekcioglu S.

Front Immunol. 2018 Sep 11;9:2029. doi: 10.3389/fimmu.2018.02029. eCollection 2018. No abstract available.

12.

RNA editing derived epitopes function as cancer antigens to elicit immune responses.

Zhang M, Fritsche J, Roszik J, Williams LJ, Peng X, Chiu Y, Tsou CC, Hoffgaard F, Goldfinger V, Schoor O, Talukder A, Forget MA, Haymaker C, Bernatchez C, Han L, Tsang YH, Kong K, Xu X, Scott KL, Singh-Jasuja H, Lizee G, Liang H, Weinschenk T, Mills GB, Hwu P.

Nat Commun. 2018 Sep 25;9(1):3919. doi: 10.1038/s41467-018-06405-9.

13.

Positive Tumor Response to Combined Checkpoint Inhibitors in a Patient With Refractory Alveolar Soft Part Sarcoma: A Case Report.

Conley AP, Trinh VA, Zobniw CM, Posey K, Martinez JD, Arrieta OG, Wang WL, Lazar AJ, Somaiah N, Roszik J, Patel SR.

J Glob Oncol. 2018 Sep;(4):1-6. doi: 10.1200/JGO.2017.009993. Epub 2017 Jul 6. No abstract available.

14.

Analysis of MDM2 Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies.

Kato S, Ross JS, Gay L, Dayyani F, Roszik J, Subbiah V, Kurzrock R.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00235. Epub 2018 Jul 13.

15.

Hypoxia-Driven Immunosuppressive Metabolites in the Tumor Microenvironment: New Approaches for Combinational Immunotherapy.

Li Y, Patel SP, Roszik J, Qin Y.

Front Immunol. 2018 Jul 16;9:1591. doi: 10.3389/fimmu.2018.01591. eCollection 2018. Review.

16.

Mining Public Databases for Precision Oncology.

Roszik J, Subbiah V.

Trends Cancer. 2018 Jul;4(7):463-465. doi: 10.1016/j.trecan.2018.04.008. Epub 2018 May 22.

PMID:
29937043
17.

Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome.

Forget MA, Haymaker C, Hess KR, Meng YJ, Creasy C, Karpinets T, Fulbright OJ, Roszik J, Woodman SE, Kim YU, Sakellariou-Thompson D, Bhatta A, Wahl A, Flores E, Thorsen ST, Tavera RJ, Ramachandran R, Gonzalez AM, Toth CL, Wardell S, Mansaray R, Patel V, Carpio DJ, Vaughn C, Farinas CM, Velasquez PG, Hwu WJ, Patel SP, Davies MA, Diab A, Glitza IC, Tawbi H, Wong MK, Cain S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Wargo JA, Radvanyi LG, Torres-Cabala CA, Beroukhim R, Hwu P, Amaria RN, Bernatchez C.

Clin Cancer Res. 2018 Sep 15;24(18):4416-4428. doi: 10.1158/1078-0432.CCR-17-3649. Epub 2018 May 30.

PMID:
29848573
18.

Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome.

Chang K, Taggart MW, Reyes-Uribe L, Borras E, Riquelme E, Barnett RM, Leoni G, San Lucas FA, Catanese MT, Mori F, Diodoro MG, You YN, Hawk ET, Roszik J, Scheet P, Kopetz S, Nicosia A, Scarselli E, Lynch PM, McAllister F, Vilar E.

JAMA Oncol. 2018 Aug 1;4(8):1085-1092. doi: 10.1001/jamaoncol.2018.1482.

PMID:
29710228
19.

mTOR at the Transmitting and Receiving Ends in Tumor Immunity.

Guri Y, Nordmann TM, Roszik J.

Front Immunol. 2018 Mar 27;9:578. doi: 10.3389/fimmu.2018.00578. eCollection 2018. Review.

20.

Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers.

Groisberg R, Hong DS, Roszik J, Janku F, Tsimberidou AM, Javle M, Meric-Bernstam F, Subbiah V.

Mol Cancer Ther. 2018 Jul;17(7):1595-1601. doi: 10.1158/1535-7163.MCT-17-1107. Epub 2018 Apr 13.

PMID:
29654067
21.

Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy.

Cascone T, McKenzie JA, Mbofung RM, Punt S, Wang Z, Xu C, Williams LJ, Wang Z, Bristow CA, Carugo A, Peoples MD, Li L, Karpinets T, Huang L, Malu S, Creasy C, Leahey SE, Chen J, Chen Y, Pelicano H, Bernatchez C, Gopal YNV, Heffernan TP, Hu J, Wang J, Amaria RN, Garraway LA, Huang P, Yang P, Wistuba II, Woodman SE, Roszik J, Davis RE, Davies MA, Heymach JV, Hwu P, Peng W.

Cell Metab. 2018 May 1;27(5):977-987.e4. doi: 10.1016/j.cmet.2018.02.024. Epub 2018 Apr 5.

PMID:
29628419
22.

A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers.

Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, Liu Y, Fan H, Shen H, Ravikumar V, Rao A, Schultz A, Li X, Sumazin P, Williams C, Mestdagh P, Gunaratne PH, Yau C, Bowlby R, Robertson AG, Tiezzi DG, Wang C, Cherniack AD, Godwin AK, Kuderer NM, Rader JS, Zuna RE, Sood AK, Lazar AJ, Ojesina AI, Adebamowo C, Adebamowo SN, Baggerly KA, Chen TW, Chiu HS, Lefever S, Liu L, MacKenzie K, Orsulic S, Roszik J, Shelley CS, Song Q, Vellano CP, Wentzensen N; Cancer Genome Atlas Research Network, Weinstein JN, Mills GB, Levine DA, Akbani R.

Cancer Cell. 2018 Apr 9;33(4):690-705.e9. doi: 10.1016/j.ccell.2018.03.014. Epub 2018 Apr 2.

23.

Impact of l-Arginine Metabolism on Immune Response and Anticancer Immunotherapy.

Kim SH, Roszik J, Grimm EA, Ekmekcioglu S.

Front Oncol. 2018 Mar 16;8:67. doi: 10.3389/fonc.2018.00067. eCollection 2018. Review.

24.

Mesenchymal Chondrosarcoma: a Review with Emphasis on its Fusion-Driven Biology.

El Beaino M, Roszik J, Livingston JA, Wang WL, Lazar AJ, Amini B, Subbiah V, Lewis V, Conley AP.

Curr Oncol Rep. 2018 Mar 26;20(5):37. doi: 10.1007/s11912-018-0668-z. Review.

PMID:
29582189
25.

Prognostic Value of PD-L1 mRNA Sequencing Expression Profile in Non-Small Cell Lung Cancer.

Sepesi B, Nelson DB, Mitchell KG, Gibbons DL, Heymach JV, Vaporciyan AA, Swisher SG, Roszik J.

Ann Thorac Surg. 2018 Jun;105(6):1621-1626. doi: 10.1016/j.athoracsur.2018.01.081. Epub 2018 Mar 3.

PMID:
29510096
26.

The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression.

Huang L, Malu S, McKenzie JA, Andrews MC, Talukder AH, Tieu T, Karpinets T, Haymaker C, Forget MA, Williams LJ, Wang Z, Mbofung RM, Wang ZQ, Davis RE, Lo RS, Wargo JA, Davies MA, Bernatchez C, Heffernan T, Amaria RN, Korkut A, Peng W, Roszik J, Lizée G, Woodman SE, Hwu P.

Clin Cancer Res. 2018 Jul 15;24(14):3366-3376. doi: 10.1158/1078-0432.CCR-17-2483. Epub 2018 Mar 1.

PMID:
29496759
27.

Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy.

Hailemichael Y, Woods A, Fu T, He Q, Nielsen MC, Hasan F, Roszik J, Xiao Z, Vianden C, Khong H, Singh M, Sharma M, Faak F, Moore D, Dai Z, Anthony SM, Schluns KS, Sharma P, Engelhard VH, Overwijk WW.

J Clin Invest. 2018 Apr 2;128(4):1338-1354. doi: 10.1172/JCI93303. Epub 2018 Feb 26.

28.

Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancers.

Kawakami M, Mustachio LM, Zheng L, Chen Y, Rodriguez-Canales J, Mino B, Kurie JM, Roszik J, Villalobos PA, Thu KL, Silvester J, Cescon DW, Wistuba II, Mak TW, Liu X, Dmitrovsky E.

Proc Natl Acad Sci U S A. 2018 Feb 20;115(8):1913-1918. doi: 10.1073/pnas.1719760115. Epub 2018 Feb 6.

29.

Cathepsin G Is Expressed by Acute Lymphoblastic Leukemia and Is a Potential Immunotherapeutic Target.

Khan M, Carmona S, Sukhumalchandra P, Roszik J, Philips A, Perakis AA, Kerros C, Zhang M, Qiao N, John LSS, Zope M, Goldberg J, Qazilbash M, Jakher H, Clise-Dwyer K, Qiu Y, Mittendorf EA, Molldrem JJ, Kornblau SM, Alatrash G.

Front Immunol. 2018 Jan 25;8:1975. doi: 10.3389/fimmu.2017.01975. eCollection 2017.

30.

Evidence for the ISG15-Specific Deubiquitinase USP18 as an Antineoplastic Target.

Mustachio LM, Lu Y, Kawakami M, Roszik J, Freemantle SJ, Liu X, Dmitrovsky E.

Cancer Res. 2018 Feb 1;78(3):587-592. doi: 10.1158/0008-5472.CAN-17-1752. Epub 2018 Jan 17. Review.

31.

The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy.

McKenzie JA, Mbofung RM, Malu S, Zhang M, Ashkin E, Devi S, Williams L, Tieu T, Peng W, Pradeep S, Xu C, Zorro Manrique S, Liu C, Huang L, Chen Y, Forget MA, Haymaker C, Bernatchez C, Satani N, Muller F, Roszik J, Kalra A, Heffernan T, Sood A, Hu J, Amaria R, Davis RE, Hwu P.

J Natl Cancer Inst. 2018 Jul 1;110(7):777-786. doi: 10.1093/jnci/djx257.

32.

mTORC2 Promotes Tumorigenesis via Lipid Synthesis.

Guri Y, Colombi M, Dazert E, Hindupur SK, Roszik J, Moes S, Jenoe P, Heim MH, Riezman I, Riezman H, Hall MN.

Cancer Cell. 2017 Dec 11;32(6):807-823.e12. doi: 10.1016/j.ccell.2017.11.011.

33.

Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors.

Dembla V, Groisberg R, Hess K, Fu S, Wheler J, Hong DS, Janku F, Zinner R, Piha-Paul SA, Ravi V, Benjamin RS, Patel S, Somaiah N, Herzog CE, Karp DD, Roszik J, Meric-Bernstam F, Subbiah V.

Sci Rep. 2017 Nov 21;7(1):15963. doi: 10.1038/s41598-017-13114-8.

34.

The Role of Next-Generation Sequencing in Sarcomas: Evolution From Light Microscope to Molecular Microscope.

Groisberg R, Roszik J, Conley A, Patel SR, Subbiah V.

Curr Oncol Rep. 2017 Oct 13;19(12):78. doi: 10.1007/s11912-017-0641-2. Review.

PMID:
29030741
35.

Alterations of microRNAs throughout the malignant evolution of cutaneous squamous cell carcinoma: the role of miR-497 in epithelial to mesenchymal transition of keratinocytes.

Mizrahi A, Barzilai A, Gur-Wahnon D, Ben-Dov IZ, Glassberg S, Meningher T, Elharar E, Masalha M, Jacob-Hirsch J, Tabibian-Keissar H, Barshack I, Roszik J, Leibowitz-Amit R, Sidi Y, Avni D.

Oncogene. 2018 Jan 11;37(2):218-230. doi: 10.1038/onc.2017.315. Epub 2017 Sep 18.

PMID:
28925390
36.

HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes.

Mbofung RM, McKenzie JA, Malu S, Zhang M, Peng W, Liu C, Kuiatse I, Tieu T, Williams L, Devi S, Ashkin E, Xu C, Huang L, Zhang M, Talukder AH, Tripathi SC, Khong H, Satani N, Muller FL, Roszik J, Heffernan T, Allison JP, Lizee G, Hanash SM, Proia D, Amaria R, Davis RE, Hwu P.

Nat Commun. 2017 Sep 6;8(1):451. doi: 10.1038/s41467-017-00449-z.

37.

Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma.

Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Chen PL, Beird HC, Garber HR, Roh W, Wani K, Chen E, Haymaker C, Forget MA, Little LD, Gumbs C, Thornton RL, Hudgens CW, Chen WS, Austin-Breneman J, Sloane RS, Nezi L, Cogdill AP, Bernatchez C, Roszik J, Hwu P, Woodman SE, Chin L, Tawbi H, Davies MA, Gershenwald JE, Amaria RN, Glitza IC, Diab A, Patel SP, Hu J, Lee JE, Grimm EA, Tetzlaff MT, Lazar AJ, Wistuba II, Clise-Dwyer K, Carter BW, Zhang J, Futreal PA, Sharma P, Allison JP, Cooper ZA, Wargo JA.

NPJ Genom Med. 2017;2. pii: 10. doi: 10.1038/s41525-017-0013-8. Epub 2017 Apr 7.

38.

Recent advances in genomic profiling of adenosquamous carcinoma of the pancreas.

Marcus R, Maitra A, Roszik J.

J Pathol. 2017 Nov;243(3):271-272. doi: 10.1002/path.4959. Epub 2017 Sep 25. Review.

PMID:
28816351
39.

Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter.

Ritthipichai K, Haymaker CL, Martinez M, Aschenbrenner A, Yi X, Zhang M, Kale C, Vence LM, Roszik J, Hailemichael Y, Overwijk WW, Varadarajan N, Nurieva R, Radvanyi LG, Hwu P, Bernatchez C.

Clin Cancer Res. 2017 Oct 15;23(20):6151-6164. doi: 10.1158/1078-0432.CCR-16-1217. Epub 2017 Jul 28.

40.

In Silico Restriction Enzyme Digests to Minimize Mapping Bias in Genomic Sequencing.

Roszik J, Fenyőfalvi G, Halász L, Karányi Z, Székvölgyi L.

Mol Ther Methods Clin Dev. 2017 Jun 24;6:66-67. doi: 10.1016/j.omtm.2017.06.003. eCollection 2017 Sep 15. Review. No abstract available.

41.

The potential role of platelets in the consensus molecular subtypes of colorectal cancer.

Lam M, Roszik J, Kanikarla-Marie P, Davis JS, Morris J, Kopetz S, Menter DG.

Cancer Metastasis Rev. 2017 Jun;36(2):273-288. doi: 10.1007/s10555-017-9678-9. Review.

PMID:
28681242
42.

Cervical Cancer Neoantigen Landscape and Immune Activity is Associated with Human Papillomavirus Master Regulators.

Qin Y, Ekmekcioglu S, Forget MA, Szekvolgyi L, Hwu P, Grimm EA, Jazaeri AA, Roszik J.

Front Immunol. 2017 Jun 16;8:689. doi: 10.3389/fimmu.2017.00689. eCollection 2017.

43.

Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles.

Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, Hinoue T, Hoadley KA, Gibb EA, Roszik J, Covington KR, Wu CC, Shinbrot E, Stransky N, Hegde A, Yang JD, Reznik E, Sadeghi S, Pedamallu CS, Ojesina AI, Hess JM, Auman JT, Rhie SK, Bowlby R, Borad MJ; Cancer Genome Atlas Network, Zhu AX, Stuart JM, Sander C, Akbani R, Cherniack AD, Deshpande V, Mounajjed T, Foo WC, Torbenson MS, Kleiner DE, Laird PW, Wheeler DA, McRee AJ, Bathe OF, Andersen JB, Bardeesy N, Roberts LR, Kwong LN.

Cell Rep. 2017 Jun 27;19(13):2878-2880. doi: 10.1016/j.celrep.2017.06.008. No abstract available.

44.

Biophysical characterization of histone H3.3 K27M point mutation.

Hetey S, Boros-Oláh B, Kuik-Rózsa T, Li Q, Karányi Z, Szabó Z, Roszik J, Szalóki N, Vámosi G, Tóth K, Székvölgyi L.

Biochem Biophys Res Commun. 2017 Aug 26;490(3):868-875. doi: 10.1016/j.bbrc.2017.06.133. Epub 2017 Jun 21.

45.

Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes.

Roszik J, Wang WL, Livingston JA, Roland CL, Ravi V, Yee C, Hwu P, Futreal A, Lazar AJ, Patel SR, Conley AP.

Clin Sarcoma Res. 2017 Jun 15;7:11. doi: 10.1186/s13569-017-0077-3. eCollection 2017.

46.

SLC45A2: A Melanoma Antigen with High Tumor Selectivity and Reduced Potential for Autoimmune Toxicity.

Park J, Talukder AH, Lim SA, Kim K, Pan K, Melendez B, Bradley SD, Jackson KR, Khalili JS, Wang J, Creasy C, Pan BF, Woodman SE, Bernatchez C, Hawke D, Hwu P, Lee KM, Roszik J, Lizée G, Yee C.

Cancer Immunol Res. 2017 Aug;5(8):618-629. doi: 10.1158/2326-6066.CIR-17-0051. Epub 2017 Jun 19.

47.

The Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non-Small Cell Lung Cancer.

Sepesi B, Gold KA, Correa AM, Heymach JV, Vaporciyan AA, Roszik J, Dmitrovsky E, Liu X.

J Thorac Oncol. 2017 Aug;12(8):1280-1287. doi: 10.1016/j.jtho.2017.05.010. Epub 2017 May 25.

48.

4-1BB-Enhanced Expansion of CD8+ TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8+ T Cells.

Harao M, Forget MA, Roszik J, Gao H, Babiera GV, Krishnamurthy S, Chacon JA, Li S, Mittendorf EA, DeSnyder SM, Rockwood KF, Bernatchez C, Ueno NT, Radvanyi LG, Vence L, Haymaker C, Reuben JM.

Cancer Immunol Res. 2017 Jun;5(6):439-445. doi: 10.1158/2326-6066.CIR-16-0364. Epub 2017 May 4.

49.

A tool for discovering drug sensitivity and gene expression associations in cancer cells.

Qin Y, Conley AP, Grimm EA, Roszik J.

PLoS One. 2017 Apr 28;12(4):e0176763. doi: 10.1371/journal.pone.0176763. eCollection 2017.

50.

Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma.

Subbiah V, Meyer C, Zinner R, Meric-Bernstam F, Zahurak ML, O'Connor A, Roszik J, Shaw K, Ludwig JA, Kurzrock R, Azad NA.

Clin Cancer Res. 2017 Aug 1;23(15):4027-4034. doi: 10.1158/1078-0432.CCR-17-0272. Epub 2017 Apr 4. Erratum in: Clin Cancer Res. 2018 Jan 15;24(2):500-501.

Supplemental Content

Loading ...
Support Center